Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis

• 0:30 – Zilucoplan approved for AChR+ myasthenia gravis
• 1:40 – James F. Howard, MD, on his immediate reaction
• 3:30 – Safety data from the RAISE trial
• 4:25 – Howard on the potential advantages of zilucoplan
• 6:50 – Phase 3 efficacy data for zilucoplan
• 7:55 – Howard with context on the efficacy and the challenges with therapeutic availability in myasthenia gravis
• 12:10 – Howard, on the future of therapeutic development

REFERENCES
1. UCB announces US FDA approval of Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis. News release. October 17, 2023. Accessed October 17, 2023. https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-US-FDA-approval-of-ZILBRYSQR-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis
2. Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalized myasthia gravis (RAISE): a randomized, double-blind, placebo-controlled, phase 3 study. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
3. Genge A, Hussain Y, Kaminski HJ, et al. Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis. Presented at: MDA 2023; February 19-22; Dallas, TX. Abstract 145.